Teva: Reports about our plans wrong

Eyal Desheh

"The company is in the process of completing its annual planning and expects to provide its full-year 2014 financial outlook in December."

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) flatly denies a press report this morning concerning its long-term forecast, according to which profits from multiple sclerosis treatment Copaxone will drop by 42% in 2014.

"The company is aware of an article published this morning by The Marker in Israel that claims to feature a copy of Teva’s long range financial planning forecast for the years 2013 through 2018. This information, which appears to be from an outdated presentation is incomplete and does not reflect our full analysis, and was provided to The Marker without Teva’s authorization. The company is extremely disappointed that confidential, potentially misleading and obsolete information was made public at this time and intends to investigate the unauthorized dissemination and publication," Teva said in a statement.

The statement goes on to say that "the company is in the process of completing its annual planning and expects to provide its full-year 2014 financial outlook in December and does not intend to comment further until then."

Published by Globes [online], Israel business news - - on November 25, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס